Trials / Completed
CompletedNCT01396447
Safety, Tolerability, and Efficacy of Cariprazine in Participants With Bipolar Depression
A Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Cariprazine in Patients With Bipolar Depression
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 584 (actual)
- Sponsor
- Forest Laboratories · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study was to evaluate the efficacy, safety, and tolerability of cariprazine relative to placebo for the treatment of participants with bipolar depression.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | Placebo was supplied in capsules. |
| DRUG | Cariprazine | Cariprazine was supplied in capsules. |
Timeline
- Start date
- 2011-07-26
- Primary completion
- 2014-01-10
- Completion
- 2014-01-10
- First posted
- 2011-07-18
- Last updated
- 2018-05-01
- Results posted
- 2018-05-01
Locations
88 sites across 6 countries: United States, Bulgaria, Canada, Colombia, Russia, Ukraine
Source: ClinicalTrials.gov record NCT01396447. Inclusion in this directory is not an endorsement.